Breaking News

Mediar, Lilly Enter Global Licensing Agreement for WISP1 Antibody

A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Mediar Therapeutics, Inc., a clinical stage biotechnology company developing first-in-class therapies designed to halt fibrosis progression, signed a global licensing agreement with Eli Lilly and Co. to advance MTX-463 into a Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF). MTX-463 is a first-in-class human IgG1 antibody designed to neutralize WISP1-mediated fibrotic signaling in several debilitating diseases. The Phase 1 study showed MTX-463 to be well-tolerated and engaged WI...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters